Loading…
Biotech developing central-nervous-system drugs for epilepsy and essential tremor, with its first products nearing approval.
Biotech developing central-nervous-system drugs for epilepsy and essential tremor, with its first products nearing approval.
Has so far depended on money raised from investors rather than product sales to pay for trials, so trial results and fundraising matter more than sales. Its drugs act on ion channels, the pores that control nerve-cell firing, and it targets groups of patients defined by a specific genetic cause. Future income would come from selling approved drugs or licensing them.
Moat: narrow (IP / patents, process know-how). Proprietary ion-channel drug-discovery platform targeting genetically defined CNS disorders.
Headquarters: Boston, Massachusetts, United States · Founded: 2015 · Employees: 168
Size Praxis Precision Medicines (PRAX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $7.75B, the 909th largest of 3,117 United States companies the cockpit tracks. Shares closed at $277.62 on 6 Nov 2026.
Performance Over six months the shares fell 15.9%, against +14.2% for the median peer and -1.1% for the United States market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue fell 100.0% over the last twelve months (peer median +10.4%).
Capital Return on invested capital runs 70.4 points below its cost of capital (19.2% WACC).
Short interest Short interest is 14.1% of the free float (15 Oct 2026).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $8.55M | $2.45M | $0 |
| Revenue growth | — | -100% | +250% | — | — |
| Gross profit | -$119,000 | -$140,000 | $8.20M | $2.02M | -$1.17M |
| EBITDA | -$378M | -$326M | -$200M | -$126M | -$214M |
| Net income | -$339M | -$303M | -$183M | -$123M | -$214M |
| Free cash flow | -$306M | -$249M | -$132M | -$110M | -$185M |
| Capital expenditure | $1.08M | $56,000 | $0 | $50,000 | $444,000 |
| Total debt | $1.09M | $110,000 | $1.37M | $2.50M | $3.50M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Praxis Precision Medicines PRAX | $7.75B | -16% | -100% | n/a | n/a | n/a |
| Jazz Pharmaceuticals Public JAZZ | $15.1B | +4% | +13% | 25% | 3.8× | -3.9% |
| Xenon Pharmaceuticals XENE | $3.79B | +4% | -100% | n/a | n/a | n/a |
| Neurocrine Biosciences NBIX | $16.7B | +8% | +38% | 25% | 4.4× | -1.7% |
| Supernus Pharmaceuticals SUPN | $5.43B | -49% | +16% | 45% | 4.1× | 4.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PRAX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.3% | +3.2% | 10th highest of 21 |
| 6-month return | -15.9% | +14.2% | 4th lowest of 21 |
| Distance from 52-week high | -29.3% | -11.5% | 6th lowest of 21 |
| Revenue growth (TTM) | -100.0% | +10.4% | lowest of 20 |
| ROIC minus cost of capital | -70.4 pp | +4.5 pp | 2nd lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Praxis Precision Medicines PRAX | United States | $7.75B | -16% | -100% | n/a | n/a | n/a | n/a |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.73B | +9% | +33% | 20% | 4.1× | 20.0% | +9.4% |
| Rhythm Pharmaceuticals RYTM | United States | $7.78B | +19% | +61% | -67% | 27.4× | n/a | n/a |
| Alkermes Public ALKS | United States | $7.71B | +31% | +15% | 5% | 4.9× | 31.5% | +7.3% |
| Corcept Therapeutics CORT | United States | $7.96B | +39% | +30% | 12% | 7.9× | 24.9% | +16.6% |
| Grifols GRF.MC | Spain | $7.49B | +23% | 0% | 16% | 2.3× | 6.8% | +7.1% |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $8.02B | +47% | +9% | 27% | 2.4× | -9.1% | +6.6% |
| Cytokinetics CYTK | United States | $7.46B | -30% | -21% | -1,046% | 111.8× | n/a | n/a |
| Kyowa Kirin 4151.T | Japan | $8.05B | +4% | +10% | 24% | 2.0× | -6.1% | +9.3% |
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $8.07B | +23% | +18% | 17% | 6.4× | n/a | n/a |
| ALK-abello A/S ALK-B.CO | Denmark | $8.14B | -5% | +17% | 27% | 7.8× | 7.6% | +12.6% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.37B | +60% | +58% | 14% | 7.2× | 9.9% | +45.5% |
| Bachem BANB.SW | Switzerland | $7.32B | +3% | +5% | 19% | 8.7× | n/a | n/a |
| Huadong Medicine 000963.SZ | China | $7.29B | -17% | +2% | 9% | 1.1× | -2.7% | +5.3% |
| Shanghai Pharmaceuticals 601607.SS | China | $8.32B | -2% | +4% | 3% | 0.3× | -10.0% | +8.1% |
| Protagonist Therapeutics PTGX | United States | $8.54B | +33% | +35% | 21% | 27.6× | 47.5% | +10.0% |
| Amneal Pharmaceuticals AMRX | United States | $7.01B | +53% | +9% | 17% | 3.2× | 15.2% | +8.7% |
| ONO Pharmaceutical 4528.T | Japan | $7.01B | +2% | -2% | 22% | 2.0× | -8.2% | +10.8% |
| RemeGen 9995.HK | Hong Kong | $6.92B | -31% | +293% | 61% | 5.1× | -4.8% | +57.9% |
| Shanghai Fosun Pharmaceutical (Group) 2196.HK | Hong Kong | $8.69B | -10% | +10% | 6% | 2.4× | 20.5% | +5.8% |
| Oruka Therapeutics ORKA | United States | $6.81B | +59% | n/a | n/a | n/a | n/a | n/a |